Soleno Therapeutics Inc
NASDAQ:SLNO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
41.51
88.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
2.3B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.3B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.4B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Soleno Therapeutics Inc
Glance View
Soleno Therapeutics Inc. is a biopharmaceutical company centered on the pressing needs of rare disease patients, most notably those with Prader-Willi syndrome (PWS). This congenital condition, characterized by an insatiable appetite leading to chronic overeating and subsequent obesity, poses significant health risks. Soleno targets this niche through its pioneering drug candidate, DCCR (diazoxide choline controlled-release), which aims to regulate appetite and improve quality of life for PWS patients. By focusing its primary efforts on this orphan indication, Soleno seeks to capitalize on favorable regulatory designations and expedited pathways, affording them advantages in both development timelines and market exclusivity. The company generates revenue through strategic partnerships, research grants, and potential future product sales, assuming regulatory approval of DCCR. One of their key strategies involves engaging with patient advocacy groups and the broader medical community to underscore the unmet needs in PWS and illustrate the potential of DCCR. Additionally, by exploring broader applications of their core technology, Soleno aims to diversify their pipeline, thus enhancing shareholder value and reinforcing their stronghold in the rare disease pharmaceutical sector. The company’s focus on innovation and collaboration, combined with a keen understanding of the regulatory landscape, positions it to navigate the complexities of biopharmaceutical market competition successfully.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Soleno Therapeutics Inc is -90.5%, which is above its 3-year median of -338.6%.
Over the last 4 months, Soleno Therapeutics Inc’s Operating Margin has increased from -586.7% to -90.5%. During this period, it reached a low of -586.7% on Jun 30, 2025 and a high of -90.5% on Oct 30, 2025.